Researchers used a 10-year Markov model to evaluate the cost-effectiveness of zolbetuximab plus CAPOX. Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ... Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease. An expert in pediatric GVHD shares his hopes and projections for the future of GVHD treatment and research. Dr. Bose joined Cancer Nursing Today at ASH 2024 to share insights on using anemia-supporting medications with ruxolitinib. Intensive nursing management during chemotherapy can greatly improve quality of life in elderly patients with gastric cancer. A recent study highlights the support needed by informal caregivers of elderly patients with gastrointestinal cancer. A new study is highlighting the important role of nursing support after gastrectomy. Irwin Walker, MBBS, joined Cancer Nursing Today at ASH 2024 to share his insights on the pilot trial and the next steps. A system based on two prognostic factors can predict the outcomes of these patients. A quantitative-qualitative survey provided insights on patient experiences, emotions, and perceptions Research presented at JADPRO Live provided insights into patient preferences surrounding treatment administration. The workshop aimed to help advanced practitioners recognize imaging findings and communicate results to patients. Chaely Medley, MSN, AGNP-C, discusses the importance of Lung Cancer Awareness Month, which is observed in November. Dr. Ehsan discusses the importance of preventing nausea and vomiting during cancer treatment and shares his approach. New research shows that quitting smoking after a cancer diagnosis can meaningfully improve survival outcomes. Almost all patients with multiple myeloma at some point will develop bone disease—the “B” in CRAB. The study explored outcomes of CBT and how it can help reduce disease burden for female patients with breast cancer. TROPiCS-02 study data shows that sacituzumab govitecan improves overall survival for HR+/HER2- metastatic breast cancer. Socioeconomic barriers and access to palliative chemotherapy affect survival outcomes for patients with cervical cancer.